Delivery Order SPE2DR25D1109-SPE2DR26FFH4B
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,721.55 for Quillivant XR 25 mg/5 ml suspension (150 ml) with a firm fixed price structure. The award was made on December 5, 2025, with an ultimate completion date of December 8, 2025. This non-set-aside contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 150 mL quantities, with a contract ceiling value of $2,802.86. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this contract—is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for Quillivant XR 25 mg/5 ml suspension (60 ml), valued at $2,361.84, with an ultimate completion date of November 5, 2025. This is a firm fixed price, non-set-aside contract representing a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) with a ceiling value of $2,328.26 on December 1, 2025, with ultimate completion scheduled for December 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,164.94 to supply Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with an ultimate completion date of November 4, 2025. This competitively awarded, firm fixed-price delivery order was issued on November 3, 2025, with no set-aside designation. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with a contract value of $1,672.09 and completion deadline of September 26, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating the award resulted from open competition. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities, with a ceiling value of $1,202.39. This firm fixed price delivery order, which will be completed by October 30, 2025, represents a non-competitive, open-market award supporting federal medical procurement needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 120ml quantity, valued at $1,378.38. The contract, executed on August 19, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 20, 2025. This award carries no set-aside designation, indicating that it was competitively awarded among eligible vendors. The place of performance is AmerisourceBergen's corporate office...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFH4BDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL) with a firm fixed price ceiling value of $2,692.46. The award was made on December 4, 2025, with an ultimate completion date of December 5, 2025. This delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical procurement under AmerisourceBergen's broader contract portfolio with the federal government. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026. The IDC serves as a comprehensive global pharmaceutical support contract enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Quillivant XR is an extended-release ADHD medication, consistent with AmerisourceBergen's role as a critical vendor supplying specialty medications, brand-name and generic drugs, and other medical commodities across multiple therapeutic domains to defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 12/3/25 |